Sage Journals: Discover world-class research

Abstract

Background:

Lacunes of presumed vascular origin are a key imaging marker of cerebral small-vessel disease (cSVD), predicting stroke and dementia risk. Their incidence and determinants have not been systematically quantified across different populations, and implications for clinical research remain unclear.

Aims:

This study aims to estimate the annualized incidence of new lacunes across diverse populations, identify study-level factors contributing to heterogeneity, summarize patient-level risk factors for incident lacunes, and provide empirical data to inform sample size estimation for studies using incident lacunes as an imaging outcome.

Summary of review:

Thirty-one studies comprising 12,646 participants and 56,073 person-years were included. The pooled overall incidence was 3.27 per 100 person-years (95% CI, 2.12–4.42), ranging from 1.50 to 8.03 across populations. Rates were highest in cSVD patients (8.03; 95% CI, 3.8–12.27), intermediate in stroke and memory-clinic patients, and lower in community-based, hypertensive, and non-specific artery disease cohorts. Meta-regression showed that baseline lacune prevalence was positively associated with incidence (β = 0.057; 95% CI, 0.006–0.108; P = 0.031). At the individual level, male sex, baseline lacunes, hypertension, and diabetes were associated with higher risk. In cSVD populations, detecting a 30% relative risk reduction required 563, 867, and 1782 participants per arm for 3-, 2-, and 1-year follow-up, respectively.

Conclusion:

Incident lacune rates vary substantially across populations and are strongly influenced by baseline lacune burden and vascular risk factors. These findings provide context for population selection and sample size considerations in studies using incident lacunes as an imaging outcome.

Graphical abstract

Keywords

Cerebral small-vessel disease lacune incidence risk factor systematic review meta-analysis

Introduction

Cerebral small-vessel disease (cSVD) is a common cause of stroke and an important contributor to cognitive decline and vascular dementia.^1–3 Lacunes of presumed vascular origin represent a key imaging marker of cSVD.⁴ Silent brain infarcts (SBI), mostly lacunes, increase the risk of subsequent stroke twofold to fourfold and double the risk of dementia, independent of cardiovascular risk factors.^5–7 These clinically unrecognized but radiologically detectable lesions occur far more frequently than symptomatic strokes, with an incidence approximately fivefold higher in the general population and even greater among patients with prior stroke.^8,9

Incident lacunes provide an objective MRI-based measure of structural brain injury progression and represent a pragmatic imaging outcome for longitudinal studies of cSVD. As visually defined lesions identifiable on MRI, they may help inform the evaluation of interventions in early-phase clinical trials, including both secondary prevention in patients with established cSVD and primary prevention in community populations.¹⁰

Despite their clinical and research significance, the incidence of lacunes and their determinants have not been systematically quantified. To address this gap, we conducted a systematic review and meta-analysis of longitudinal MRI studies to: (1) estimate annualized incidence rates of new lacunes across diverse populations; (2) identify study-level factors underlying heterogeneity; (3) summarize reported patient-level risk factors for incident lacunes; and (4) provide empirical sample size estimates for studies using incident lacunes as an imaging outcome.

Methods

This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines¹¹ and was registered with PROSPERO, the International Prospective Register of Systematic Reviews (CRD420251158772). The data that support the findings of this study are available from the authors upon reasonable request.

Literature search and study eligibility

We systematically searched MEDLINE, Embase, and the Cochrane Library from inception to 25 September 2025, for full-text English-language articles. The search strategy combined terms related to incident lacunes, longitudinal follow-up, and brain MRI (Table S1). Reference lists of all eligible studies and relevant reviews were manually screened to identify additional records. Two reviewers (F.H. and D.Z.) independently screened all records for eligibility; any discrepancies were resolved through discussion and consensus.

We included longitudinal studies in adults, encompassing observational cohorts and randomized controlled trials (RCTs), that reported new (incident) lacunes on follow-up MRI, defined as subcortical, fluid-filled (cerebrospinal fluid-like) cavities <20 mm in diameter. Studies reporting only incident ischemic lesions (e.g. DWI-positive lesions or new non-cavitated white matter hyperintensities [WMH]) or only SBIs without separately defining lacunes were excluded. We also excluded those focusing on hereditary cSVD, cerebral amyloid angiopathy, or cohorts primarily investigating cardioembolic sources (e.g. atrial fibrillation, patent foramen ovale, valvular disease, and heart failure), cranial artery stenosis, or recent endovascular or cardiac procedures. Finally, studies with follow-up <6 months, sample size <50, as well as reviews, case reports, conference abstracts, and cross-sectional designs, were excluded.

Data extraction

Data were extracted independently by two reviewers (F.H. and D.Z.) using a standardized template. When multiple publications described the same cohort, the article with the largest sample size was selected. Studies were categorized by population type, including community-based cohorts; cSVD cohorts, defined by clinical lacunar stroke, recent small subcortical infarcts (RSSI) on brain imaging, or chronic imaging markers (e.g. WMHs), with heterogeneous inclusion criteria; all-cause stroke populations; memory-clinic patients or individuals with cognitive complaints; participants with vascular risk factors such as hypertension; and those with non-specific artery disease. For each study, we recorded the baseline prevalence of lacunes and the number of MRI scans during follow-up. In RCTs, data from different trial arms were combined when no significant between-group differences were reported. Reported patient-level risk factors were extracted. Post-treatment indicators, such as achieved blood pressure or lipid levels, were also collected when reported.

Quality assessment

Risk of bias was independently assessed by two reviewers (F.H. and D.Z.) using the modified Newcastle-Ottawa Scale.¹² The scale comprises three domains: selection, comparability, and outcome, with a maximum score of 8 points.

Statistical analysis

For each study, the annualized incidence of lacunes was calculated as the number of new lacunes divided by total person-years. Pooled incidence rates with 95% confidence intervals (CIs) were estimated using random-effects meta-analysis with each study weighted according to its sample size and accumulated person-years, using restricted maximum likelihood (REML) variance estimation and Hartung–Knapp adjustment. Prespecified subgroup analyses were conducted by study population, and heterogeneity quantified using I2 and τ2.

To explore sources of heterogeneity, multivariate mixed-effects meta-regression models were fitted with hypothesis-driven predictors, including study population, mean age, sex proportion, mean follow-up duration, and number of MRI scans. REML estimation with Knapp–Hartung adjustment was applied, and the proportion of explained variance was reported. The association between baseline prevalence and incidence of lacunes was evaluated using weighted linear regression. Study-level associations of imaging and study design factors (number of MRI scans, MRI field strength, and publication year) with incidence were further examined using Pearson correlation. For patient-level risk factors reported in ⩾2 studies, odds ratios (ORs) were pooled using random-effects models and presented as forest plots.

To informing sample size estimation, we modeled a hypothetical two-arm trial with balanced allocation, using incident lacunes as an imaging outcome. Based on pooled annual incidence rates, we estimated per-arm sample sizes required to detect relative risk reductions of 30%, 25%, 20%, 15% and 10% at 1-, 2-, and 3-year follow-up periods, assuming 80% power and two-sided α = 0.05. Estimates were further stratified by baseline lacune prevalence.

Publication bias was assessed using funnel plots and Egger’s test when more than 10 studies were available. All analyses were performed in R (version 4·4·2), with two-sided p < 0.05 considered significant.

Results

Figure 1 shows the study selection process. Of 8406 records identified, 1960 duplicates were removed, leaving 6446 for title and abstract screening, of which 6304 were excluded. Among 142 articles reviewed in full text, 92 were excluded for being cross-sectional, focusing on large-artery or cardioembolic etiologies, or representing duplicate cohorts. Of 50 studies reporting incident infarcts, 19 were further excluded due to follow-up <6 months, sample size <50, or reporting only silent or covert infarcts rather than lacunes. Ultimately, 31 independent studies were included (Table 1), with detailed quality assessments provided in Tables S2 and S3 in the supplemental material.

Figure 1.

Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram of study selection.

Table 1.

Study characteristics.

Author, year	Country	Study name or site	N	Mean age	Men (%)	Mean follow-up (years)	Newlacune (N)	Incidence of lacune/100 person-years	Baseline lacune (%)	No. of scans	Field strength	Slice thickness (T1WI, mm)	Size of lacune (mm)
Community-based cohort
Akoudad, 2014¹³	Netherlands	Rotterdam study^*	803	68.3	49	3.4	20	0.73	7.3	2	1.5 T	1.6	3–15
Chen, 2009¹⁴	Australia	PATH TLS	375	62.6	53	4	6	0.40	7.8	2	1.5 T	2	3–20
Cheung, 2010¹⁵	US	ARIC	810	61.6	40	10.5	131	1.54	0	2	1.5 T	5	3–20
Elmstahl, 2024¹⁶	Sweden	GAS	241	76.3	41	5.9	20	1.41	11	2	3 T	3–5	<10
Li, 2022¹⁷	Sweden	SNAC-K	325	70	40	5.7	42	2.27	20.9	3	1.5 T	1.5	3–15
Liu, 2023¹⁸	China	Chinese cohort	423	67	41	5	159	7.52	9.5	4	3 T	1	3–15
Longstreth, 2002¹⁹	US	CHS	1433	74	40	5	209	2.92	0	2	1.5 T	5	3–20
Nylander, 2017²⁰	Sweden	PIVUS	252	75		5	26	2.06	21	2	1.5 T	3	3–15
Pan, 2024²¹	China	Shunyi study	756	53.7	35	5.6	78	1.85	11.6	2	3 T	1.3	3–15
Schmidt, 2006²²	Austria	ASPS	164	63.9	46.3	6	5	0.50	6.9	3	1.5 T	5	<10
van Dalen, 2017²³	Netherlands	preDIVA	126	77	47	3	8	2.12	7	2	3 T	1.2	3–15
Vermeer, 2003²⁴	Netherlands	Rotterdam study^†	668	71	48	3.4	83	3.65	21.7	2	1.5 T	5	3–20
Xia, 2020²⁵	China	Chinese cohort	191	68	44	6.9	19	1.44	11.5	2	1.5/3 T	1.2	3–15
Cerebral small-vessel disease
Cai, 2022²⁶	Netherlands	RUN-DMC^‡	382	64.1	57	11.2	52	1.22	24.1	4	1.5 T	5	3–15
Gouw, 2008²⁷	Europe	LADIS^‡	396	73.6	46	3.1	75	6.11	47.7	2	0.5/1.5 T	5	3–10
Grosset, 2025²⁸	France	DHU-LAC^§	172	63	72	0.6	18	17.44	/	2	3 T	/	3–15
Mena, 2024²⁹	Spain	Moisès Broggi Hospital^§	92	67	70	2	15	8.15	51.1	2	1.5 T	5	3–15
Staszewski, 2018³⁰	Poland	SHEF-SVD^‡	123	72.2	51	2	25	10.16	48.8	2	/	/	3–15
Zeestraten, 2017⁸	UK	SCANS^§	99	68.9	67	3	27	9.09	/	4	1.5 T	/	3–15
Zhou, 2019³¹	China	CIRCLE^§	64	56.3	52	2.5	16	10	49.8	2	3 T	1	3–15
All-cause stroke
Cavalieri, 2012³²	Austria	VITATOPS	359	64.3	64	2	25	3.48	36.2	2	1.5 T	/	⩽15
Jiang, 2022³³	China	Ruijin Hospital	225	65.7	66	2	25	5.6	63.1	2	3 T	2	⩽20
Memory-clinic patients
Goos, 2010³⁴	Netherlands	VU University Medical Center, Amsterdam	254	66	52	1.9	9	1.86	14.6	2	1.0 T	5	3–15
Gyanwali, 2021³⁵	Singapore	National University Hospital, Singapore	434	74	45	2	25	2.88	25.6	2	3 T	/	3–15
Richard, 2010³⁶	Netherlands	EVA study	65	76	48	2	12	9.23	30.8	2	/	/	/
Hypertension
Ji, 2018³⁷	China	Shandong area	668	78	52	5.2	65	1.89	/	3	3 T	2	3–15
Kern, 2024³⁸	US	SPRINT	450	67	63	3.9	6	0.34	11	2	3 T	/	3–15
Shintani, 1998³⁹	Japan	Toride Kyodo General Hospital	98	64	50	2.5	12	4.9	71.4	4	0.5 T	/	/
Uiterwijk, 2017⁴⁰	Netherlands	HYBRiD	90	56.2	57.8	4	5	1.39	23.3	2	1.5 T	/	3–15
Non-specific artery disease
Sharma, 2020⁴¹	Global	COMPASS^\|\|	1445	71	77	2	19	0.66	/	2	1~3 T	3–5	⩽15
van, 2014⁴²	Netherlands	SMART^#	663	57	81	3.8	60	2.38	8.3	2	1.5 T	4	3–15

Baseline scan: 2005–2006; ^†Baseline scan: 1995–1996; ^‡Chronic stage; ^§Lacunar stroke or recent small subcortical infarct;^||Stable coronary artery disease or peripheral artery disease; ^#Coronary artery disease, cerebrovascular disease, peripheral artery disease, and/or an abdominal aortic aneurysm.

Abbreviations: cSVD, cerebral small-vessel disease; PATH TLS, PATH Through Life Study; ARIC, Atherosclerosis Risk in Communities Brain Magnetic Resonance Imaging Study; GAS, Good Aging in Skåne; SNAC-K, Swedish National study on Aging and Care in Kungsholmen; CHS, Cardiovascular Health Study; PIVUS, Prospective Investigation of the Vasculature in Uppsala Seniors; ASPS, Austrian stroke prevention study; preDIVA, Prevention of Dementia by Intensive Vascular Care; RUN-DMC, Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort; LADIS, The Leukoaraiosis and Disability Study; SCANS, St George’s Cognition and Neuroimaging in Stroke; VITATOPS, The VITAmins TO Prevent Stroke; EVA, Evaluation of Vascular Care in Alzheimer’s Disease; SPRINT, Systolic Pressure Intervention Trial; HYBRiD, hypertension and brain damage study; COMPASS, Cardiovascular Outcomes for People Using Anticoagulation Strategies; SMART, Second Manifestations of ARTerial disease.

Incidence of lacunes

Across 31 studies, a total of 12,646 participants were followed for 56,073 person-years, with a median follow-up of 3.4 years (range, 0.6–11.2). Publication bias was assessed within each population subgroup. Among community cohorts, no significant funnel-plot asymmetry was detected (Figure S1; Egger’s test: t = 2.12, p = 0.06).

The overall pooled annualized incidence was 3.27 (95% CI, 2.12–4.42) per 100 person-years. Incident lacune rates varied across populations (Figure 2 and Table 2). The highest was observed in cSVD cohorts (n = 1328; 8.03 per 100 person-years; 95% CI, 3.8–12.27), followed by all-cause stroke (n = 584; 4.34; 95% CI, 0–17.31) and memory-clinic patients (n = 753; 3.86; 95% CI, 0–12.56). Rates were lower in community cohorts (n = 6567; 2.14; 95% CI, 1.05–3.24), hypertensive patients (n = 1306; 1.72; 95% CI, 0–4.37), and in those with non-specific artery disease (n = 2108; 1.50; 95% CI, 0–12.45). In multivariate meta-regression adjusting for age, sex, number of MRI scans, and follow-up duration, cSVD cohorts showed significantly higher incidence rates than community-based and hypertension cohorts. Longer follow-up was associated with a lower annualized incidence (β = −0.19 per year; 95% CI, −0.30 to −0.07; p = 0.003), and the model explained 52.4% of between-study heterogeneity (F-statistic 4.10 on 9 and 20 degrees of freedom, p = 0.004).

Figure 2.

Pooled annualized incidence rates of lacunes by study population.

Table 2.

Annualized lacune incidence for studies assessing different populations.

Population	No. of studies (patients)	Incident lacune /100 person-year	Versus community		Versus non-specific artery disease		Versus hypertension		Versus memory clinic		Versus stroke
Population	No. of studies (patients)	Incident lacune /100 person-year	RR (95% CI)^*	P value	RR (95% CI)^*	P value	RR (95% CI)^*	P value	RR (95% CI)^*	P value	RR (95 % CI)^*	P value
cSVD	7 (1328)	8.03 (3.8–12.27)	2.97 (1.31–6.75)	0.012	2.42 (0.73–8.08)	0.142	3.78 (1.72–8.31)	0.002	2.51 (0.94–6.71)	0.065	1.55 (0.58–4.10)	0.362
Stroke	2 (584)	4.34 (0.00–17.31)	1.92 (0.58–6.36)	0.268	1.57 (0.43–5.74)	0.480	2.45 (0.79–7.54)	0.113	1.62 (0.46–5.75)	0.433
Memory clinic	3 (753)	3.86 (0.00–12.56)	1.18 (0.49–2.83)	0.692	0.96 (0.19–4.89)	0.963	1.51 (0.53–4.30)	0.426
Hypertension	4 (1306)	1.72 (0.00–4.37)	0.79 (0.33–1.88)	0.571	0.64 (0.16-2.57)	0.512
Non-specific artery disease	2 (2108)	1.50 (0.00–12.45)	1.23 (0.25–5.99)	0.790
Community	13 (6567)	2.14 (1.05–3.24)

Derived from multivariate mixed-effects meta-regression models adjusted for mean age, sex proportion, number of MRI scans, and mean follow-up duration. Abbreviations: cSVD, cerebral small-vessel disease; RR, relative risk; CI, confidence interval.

Baseline lacune prevalence was significantly associated with higher incidence in weighted regression (β = 0.057; 95% CI, 0.006–0.108; p = 0.031; adjusted R²= 0.14) and showed a similar positive relationship in Pearson correlation analysis (r = 0.67; 95% CI, 0.38–0.83; p < 0.001; Figure 3). In contrast, incidence was not significantly related to the number of MRI scans, MRI field strength, or publication year.

Figure 3.

Bubble plots of annualized incidence of lacunes versus baseline lacune prevalence. Plot points are scaled by total person-years of follow-up and colored by study population. Dashed lines show fitted associations within each population group.

Patient risk factors associated with incident lacunes

Across studies, baseline lacunes (OR, 2.24; 95% CI, 1.01–4.99) and male sex (OR, 1.43; 95% CI, 1.05–1.95) were significantly associated with an increased risk of incident lacunes, whereas age showed no significant effect (Figure 4(a)). Among modifiable factors (Figure 4(b)), hypertension (OR, 1.78; 95% CI, 1.24–2.56) and diabetes (OR, 1.69; 95% CI, 1.09–2.63) were associated with higher risk, while hyperlipidemia, smoking, and body mass index were not. Most studies did not account for how well these risk factors were controlled. In those that reported post-treatment indicators, higher blood pressure (OR, 1.30; 95% CI, 1.10–1.53) and elevated homocysteine levels (OR, 1.37; 95% CI, 1.00–1.87) were significantly associated with incident lacunes, whereas total cholesterol was not.

Figure 4.

Effect sizes and meta-analysis results for risk factors of incident lacune: (a) non-modifiable factors and (b) modifiable factors.

Estimated sample sizes using incident lacunes as an imaging outcome

Sample size requirements varied markedly across populations (Table 3). Among patients with cSVD, detecting a 30% relative risk reduction in incident lacunes would require approximately 563, 867, and 1782 participants per arm for 3-, 2-, and 1-year follow-up, respectively. Stratification by baseline lacune prevalence revealed substantial variation (Figure S2): populations with a baseline prevalence of 45%–60% required approximately 75% fewer participants than those with a prevalence below 15% to detect the same 30% effect over 3 years (652 vs. 2716 per arm).

Table 3.

Estimated prospective sample sizes (per arm) necessary to detect significant reductions in incident lacunes at different follow-up duration, stratified by study population, at power = 0.8 and α = 0.05.

Population	Follow-up time	Treatment effect sizes
Population	Follow-up time	30%	25%	20%	15%	10%
Cerebral small-vessel disease	3 years	563	831	1329	2415	5546
	2 years	867	1283	2057	3748	8630
	1 year	1782	2643	4247	7755	17,899
All-cause stroke	3 years	1081	1601	2568	4683	10,792
	2 years	1645	2440	3919	7155	16,510
	1 year	3339	4958	7975	14,575	33,673
Hypertension	3 years	2801	4157	6686	12,216	28,218
	2 years	4226	6276	10,097	18,458	42,656
	1 year	8502	12,631	20,332	37,187	85,975

Discussion

This systematic review provides a comprehensive synthesis of the incidence and determinants of MRI-defined incident lacunes. Across 31 longitudinal studies involving more than 12,000 participants, the pooled overall incidence was 3.27 per 100 person-years, ranging from 1.5 to 8 across populations. The highest rates were observed in patients with cSVD, approximately 3.75 times higher than in older community-dwelling populations. Male sex, baseline lacune burden, and vascular risk factors, particularly hypertension and diabetes, were associated with increased risk. Furthermore, our analyses provide empirical data to inform the sample size estimation and the design of clinical studies that consider incident lacunes as an imaging outcome thereby offering methodological insights relevant to cSVD research.

Incidence varied substantially across populations. Patients with established cSVD, defined by clinical lacunar stroke or RSSI on imaging, or by chronic MRI markers, had the highest rates. Patients with all-cause stroke and those with cognitive complaints showed intermediate rates, whereas incidence was relatively low in community populations and hypertension cohorts. The non-specific artery disease group, which specifically included individuals with large-artery atherosclerosis (coronary artery and peripheral artery), showed the lowest incidence, indicating that large-vessel atherosclerosis does not necessarily translate into a high risk of lacunes or cSVD progression,^41,42 consistent with the non-atheromatous pathology of cSVD. These findings underscore the importance of population selection when interpreting incidence estimates or designing studies using incident lacunes as an outcome.

The inverse association between follow-up duration and annualized incidence likely reflects a “front-loaded” risk pattern in cSVD. Early after an index event, for example, a clinical lacunar stroke, new ischemic lesions may indicate an active disease phase, with risk declining as the condition stabilizes. This interpretation is supported by a longitudinal study of patients with mild stroke enriched for cSVD, showing that although incident DWI-positive infarcts occurred throughout the year, most incident infarcts, particularly small subcortical ones, occurred within the first 3 months after the index stroke, despite optimal guideline-based secondary prevention.⁴³ Such early clustering of incident ischemia may explain the higher annualized rates observed in studies with shorter follow-up, whereas longer follow-up intervals diluted this early peak. Therefore, sample size estimations based on annualized incidence rates should be interpreted with caution.

Both the between-study meta-regression and pooled individual-level analyses demonstrated that a higher baseline lacune burden was significantly associated with an increased risk of incident lacunes. This suggests that pre-existing lacunes are not merely markers of past injury but indicate an ongoing process of small-vessel damage or a predisposition to tissue cavitation and new lacune formation. It underscores the prognostic value of baseline MRI markers for risk stratification: patients with existing lacunes represent a higher-risk subgroup in whom intensive vascular risk factor management and closer imaging surveillance may be particularly warranted.

These findings have implications for designing clinical studies and trials that consider incident lacunes as a pragmatic imaging outcome. Baseline lacune burden should be considered both as a potential effect modifier and as a key determinant of sample size. The disease stage at recruitment warrants careful consideration. Enrolling patients at an early, “community-population” stage may enable intervention before irreversible damage occurs, but the lower incidence necessitates larger sample sizes or longer follow-up to detect meaningful effects. Conversely, recruiting patients with a higher burden, for example, those with “active cSVD,” yields higher event rates and smaller sample requirements, but the therapeutic benefits may diminish once microvascular damage has advanced. Balancing early intervention against trial feasibility will, therefore, be critical. Moreover, combining incident lacunes with other imaging markers, such as WMH progression, or incorporating them into summary cSVD scores, may further improve research efficiency and clinical relevance.^44,45

Several explanations may account for the lack of an independent association between age and incident lacunes. Many included studies enrolled relatively older participants with restricted age ranges, and age is closely correlated with baseline lacune burden, which may attenuate its independent effect in adjusted analyses. Survivor bias may also contribute, with individuals at higher risk being underrepresented at older ages. Furthermore, the type of participant recruitment setting could play a role: studies recruiting participants from stroke clinics, for example, might enroll individuals who are more likely to present with lacunes and develop incident lacunes at younger ages, thereby skewing the age-lacune association.

The association between male sex and incident lacunes aligns with prior evidence that men are more likely to develop lacunar stroke and exhibit a greater cSVD burden, consistent with meta-analytic data demonstrating a male predominance in cSVD severity.⁴⁶ This sex-related susceptibility may reflect underlying biological differences, including lipid metabolism and endothelial function. Supporting this, a large metabolomic study identified sex-specific associations between circulating metabolites, specifically, higher levels of hydroxyphenylpyruvate and lower levels of lysophosphatidylcholines and hydroxysphingomyelins, that were strongly associated with WMH in men but not in women.⁴⁷

Hypertension, diabetes, higher achieved blood pressure, and homocysteine level were associated with a higher risk of incident lacunes, highlighting the importance of vascular risk management in slowing cSVD progression and preventing recurrent injury. This aligns with findings from the Systolic Blood Pressure Intervention Trial, which reported less WMH progression with intensive blood pressure reduction.⁴⁸ However, no RCTs have yet demonstrated that blood pressure lowering, smoking cessation, diabetes management, or lifestyle modification can effectively reduce the incidence of lacunes.⁴⁹

This study has several notable strengths. We conducted a comprehensive, protocol-registered systematic review and meta-analysis in accordance with PRISMA guidelines. All records were independently screened by two reviewers, with discrepancies resolved through consensus. A rigorous risk-of-bias assessment was applied, and random-effects models with Knapp–Hartung adjustment were used to generate robust pooled estimates. Beyond study-level meta-regression, we synthesized individual-level risk factors, providing consistent evidence from both between-study and within-study analyses.

Several limitations should be acknowledged. First, heterogeneity in MRI protocols, omission of small lacunes, and differences in follow-up imaging frequency may have influenced pooled incidence estimates. Stratified analyses by ethnicity or lacune location were not feasible because of inconsistent reporting and limited sample sizes within subgroups. Furthermore, MRI-defined lacunes may arise from heterogeneous underlying processes and should, therefore, be interpreted as a pragmatic composite imaging outcome rather than a biologically homogeneous entity. Second, although annualized incidence rates facilitated comparison across studies, this approach assumes a constant rate over time and may not fully capture periods of hyperactive or quiescent disease activity. Third, data for several individual risk factors were limited. Finally, the work does not apply to incident DWI-positive lesions or small subcortical infarcts that did not cavitate. Moreover, some studies reported only SBIs or ischemic lesions without separately defining lacunes; excluding these studies may have introduced selection bias.

In conclusion, incident lacunes occur at markedly variable rates across populations and are closely associated with baseline lacune burden. Male sex, hypertension, and diabetes are key risk factors. These findings highlight the importance of controlling modifiable vascular risk factors and provide empirical data to inform sample size estimation and the design of studies using incident lacunes as an imaging outcome.

Supplemental Material

sj-pdf-1-wso-10.1177_17474930261421046 – Supplemental material for Rates and determinants of incident lacunes: A systematic review and meta-analysis

Supplemental material, sj-pdf-1-wso-10.1177_17474930261421046 for Rates and determinants of incident lacunes: A systematic review and meta-analysis by Fei Han, Ding-Ding Zhang and Joanna M Wardlaw in International Journal of Stroke

Footnotes

Contributors

F.H. designed the study, performed the literature search, extracted the data, analyzed the data, and wrote the first draft of the manuscript; D.-D.Z. performed the literature search, extracted the data, and supervised the statistical analyses; J.M.W. supervised the study and critically reviewed the article.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was funded by the National Natural Science Foundation of China (No. 82271368, 82571510), National High-Level Hospital Clinical Research Funding (2025-PUMCH-A-151), and Peking Union Medical College Hospital Talent Cultivation Program (UBJ11275).

ORCID iDs

Fei Han

Joanna M Wardlaw

Data availability

The data will be made available upon reasonable request.

Supplemental material

Supplemental material for this article is available online.

References

Hamilton

OKL

Backhouse

Janssen

, et al. Cognitive impairment in sporadic cerebral small vessel disease: a systematic review and meta-analysis. Alzheimer’s Dement 2021; 17: 665–685.

Wardlaw

Smith

Dichgans

Small vessel disease: mechanisms and clinical implications. Lancet Neurol 2019; 18: 684–696.

Debette

Schilling

Duperron

, et al. Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis. JAMA Neurol 2019; 76: 81–94.

Duering

Biessels

Brodtmann

, et al. Neuroimaging standards for research into small vessel disease—advances since 2013. Lancet Neurol 2023; 22: 602–618.

Gupta

Giambrone

Gialdini

, et al. Silent brain infarction and risk of future stroke: a systematic review and meta-analysis. Stroke 2016; 47: 719–725.

Vermeer

Longstreth

Jr Koudstaal

PJ.

Silent brain infarcts: a systematic review. Lancet Neurol 2007; 6: 611–619.

Vermeer

Prins

den Heijer

, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215–1222.

Zeestraten

Lawrence

Lambert

, et al. Change in multimodal MRI markers predicts dementia risk in cerebral small vessel disease. Neurology 2017; 89: 1869–1876.

Wolfe

Giroud

Kolominsky-Rabas

, et al. Variations in stroke incidence and survival in 3 areas of Europe. Stroke 2000; 31: 2074–2079.

10.

Markus

van Der Flier

Smith

, et al. Framework for clinical trials in cerebral small vessel disease (FINESSE): a review. JAMA Neurol 2022; 79: 1187–1198.

11.

Liberati

Altman

Tetzlaff

, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.

12.

Wells

Shea

Higgins

Sterne

Tugwell

Reeves

BC.

Checklists of methodological issues for review authors to consider when including non-randomized studies in systematic reviews. Res Synth Methods 2013; 4: 63–77.

13.

Akoudad

Ikram

Koudstaal

, et al. Cerebral microbleeds are associated with the progression of ischemic vascular lesions. Cerebrovasc Dis 2014; 37: 382–388.

14.

Chen

Wen

Anstey

, et al. Prevalence, incidence, and risk factors of lacunar infarcts in a community sample. Neurology 2009; 73: 266–272.

15.

Cheung

Mosley

Islam

, et al. Retinal microvascular abnormalities and subclinical magnetic resonance imaging brain infarct: a prospective study. Brain 2010; 133: 1987–1993.

16.

Elmståhl

Ellström

Siennicki-Lantz

, et al. Incidence of cerebral small vessel disease-related MR markers in the Swedish general population ‘Good Aging in Skåne’ (GÅS) study. J Neurol 2024; 271: 5997–6003.

17.

Kalpouzos

Laukka

, et al. Progression of neuroimaging markers of cerebral small vessel disease in older adults: a 6-year follow-up study. Neurobiol Aging 2022; 112: 204–211.

18.

Liu

Zhang

Xing

, et al. Excessive salt intake accelerates the progression of cerebral small vessel disease in older adults. BMC Geriatr 2023; 23: 263.

19.

Longstreth

Jr Dulberg

Manolio

, et al. Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the cardiovascular health study. Stroke 2002; 33: 2376–2382.

20.

Nylander

Fahlström

Rostrup

, et al. Quantitative and qualitative MRI evaluation of cerebral small vessel disease in an elderly population: a longitudinal study. Acta Radiol 2018; 59: 612–618.

21.

Pan

Zhang

Liu

, et al. Risk factor differences in five-year progression of Intracranial artery stenosis and cerebral small vessel disease in general population. BMC Neurol 2024; 24: 328.

22.

Schmidt

Pichler

, et al. C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: results of the Austrian Stroke Prevention Study. Stroke 2006; 37: 2910–2916.

23.

van Dalen

Moll

van

Charante

Caan

MWA

, et al. Effect of long-term vascular care on progression of cerebrovascular lesions: magnetic resonance imaging substudy of the PreDIVA Trial (Prevention of Dementia by Intensive Vascular Care). Stroke 2017; 48: 1842–1848.

24.

Vermeer

Den Heijer

Koudstaal

, et al. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2003; 34: 392–396.

25.

Xia

Shen

Wang

, et al. White matter hyperintensities associated with progression of cerebral small vessel disease: a 7-year Chinese urban community study. Aging (Albany NY) 2020; 12: 8506–8522.

26.

Cai

Jacob

van Loenen

, et al. Determinants and temporal dynamics of cerebral small vessel disease: 14-year follow-up. Stroke 2022; 53: 2789–2798.

27.

Gouw

van der Flier

Fazekas

, et al. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke 2008; 39: 1414–1420.

28.

Grosset

Dimitrovic

Guillonnet

, et al. MRI-proven incident ischemia: a new marker of disease progression in small vessel diseases. Stroke 2025; 56: 39–45.

29.

Mena

Mengual

García-Sánchez

, et al. Relationship of arterial stiffness and baseline vascular burden with new lacunes and microbleeds: a longitudinal cohort study. Eur Stroke J 2024; 9: 251–258.

30.

Staszewski

Piusińska-Macoch

Brodacki

Skrobowska

Stępień

IL-6, PF-4, sCD40 L, and homocysteine are associated with the radiological progression of cerebral small-vessel disease: a 2-year follow-up study. Clin Interv Aging 2018; 13: 1135–1141.

31.

Zhou

Zhang

, et al. Role of deep medullary veins in pathogenesis of lacunes: longitudinal observations from the CIRCLE study. J Cereb Blood Flow Metab 2020; 40: 1797–1805.

32.

Cavalieri

Schmidt

Chen

, et al. B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy. Stroke 2012; 43: 3266–3270.

33.

Jiang

Yao

Huang

Zhang

Shen

Weng

Longitudinal white matter hyperintensity changes and cognitive decline in patients with minor stroke. Aging Clin Exp Res 2022; 34: 1047–1054.

34.

Goos

Henneman

Sluimer

, et al. Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology 2010; 74: 1954–1960.

35.

Gyanwali

Lai

MKP

Lui

, et al. Blood-based cardiac biomarkers and the risk of cognitive decline, cerebrovascular disease, and clinical events. Stroke 2021; 52: 2275–2283.

36.

Richard

Gouw

Scheltens

van Gool

WA.

Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the evaluation of vascular care in Alzheimer’s disease (EVA) study. Stroke 2010; 41: 554–556.

37.

Zhao

Wang

, et al. Effect of low-dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. J Am Med Dir Assoc 2018; 19: 995–1002.

38.

Kern

Nasrallah

Bryan

, et al. Intensive blood pressure treatment and subclinical brain infarcts: a secondary analysis of SPRINT (Systolic Pressure Intervention Trial). Ann Neurol 2024; 95: 866–875.

39.

Shintani

Shiigai

Arinami

Subclinical cerebral lesion accumulation on serial magnetic resonance imaging (MRI) in patients with hypertension: risk factors. Acta Neurol Scand 1998; 97: 251–256.

40.

Uiterwijk

Staals

Huijts

de Leeuw

Kroon

van Oostenbrugge

RJ.

MRI progression of cerebral small vessel disease and cognitive decline in patients with hypertension. J Hypertens 2017; 35: 1263–1270.

41.

Sharma

Hart

Smith

, et al. Rivaroxaban for prevention of covert brain infarcts and cognitive decline: the COMPASS MRI substudy. Stroke 2020; 51: 2901–2909.

42.

van der Veen

Muller

Vincken

, et al. Longitudinal changes in brain volumes and cerebrovascular lesions on MRI in patients with manifest arterial disease: the SMART-MR study. J Neurol Sci 2014; 337: 112–118.

43.

Clancy

Arteaga-Reyes

Jaime Garcia

, et al. Incident infarcts in patients with stroke and cerebral small vessel disease: frequency and relation to clinical outcomes. Neurology 2024; 103: e209750.

44.

Brown

Low

Markus

HS.

Rate of, and risk factors for, white matter hyperintensity growth: a systematic review and meta-analysis with implications for clinical trial design. J Neurol Neurosurg Psychiatry 2021; 92: 1271–1277.

45.

Jochems

ACC

Arteaga

Chappell

, et al. Longitudinal changes of white matter hyperintensities in sporadic small vessel disease: a systematic review and meta-analysis. Neurology 2022; 99: e2454–e2463.

46.

Jiménez-Sánchez

Hamilton

OKL

Clancy

, et al. Sex differences in cerebral small vessel disease: a systematic review and meta-analysis. Front Neurol 2021; 12: 756887.

47.

Sliz

Shin

Ahmad

, et al. Circulating metabolome and white matter hyperintensities in women and men. Circulation 2022; 145: 1040–1052.

48.

Group SPRINT MIND; Nasrallah

Pajewski

, et al. Association of intensive vs standard blood pressure control with cerebral white matter lesions. JAMA 2019; 322: 524–534.

49.

Wardlaw

Debette

Jokinen

, et al. ESO Guideline on covert cerebral small vessel disease. Eur Stroke J 2021; 6: CXI-CLXII.